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Activators of liver X receptors (LXR) stimulate epi-
dermal di¡erentiation and development, but inhibit
keratinocyte proliferation. In this study, the anti-in-
£ammatory e¡ects of two oxysterols, 22(R)-hydroxy-
cholesterol (22ROH) and 25-hydroxycholesterol (25OH),
and a nonsterol activator of LXR, GW3965, were exam-
ined utilizing models of irritant and allergic contact
dermatitis. Irritant dermatitis was induced by applying
phorbol 12-myristate-13-acetate(TPA) to the surface of
the ears of CD1 mice, followed by treatment with
22ROH, 25OH, GW3965, or vehicle alone. Whereas
TPA treatment alone induced an E2-fold increase in
ear weight and thickness, 22ROH, 25OH, or GW3965
markedly suppressed the increase (greater than 50% de-
crease), and to an extent comparable to that observed
with 0.05% clobetasol treatment. Histology also re-
vealed a marked decrease inTPA-induced cutaneous in-
£ammation in oxysterol-treated animals. As topical
treatment with cholesterol did not reduce the TPA-in-
duced in£ammation, and the nonsterol LXR activator
(GW3965) inhibited in£ammation, the anti-in£amma-
tory e¡ects of oxysterols cannot be ascribed to a non-
speci¢c sterol e¡ect. In addition, 22ROH did not
reduce in£ammation in LXRb / or LXRab / an-
imals, indicating that LXRb is required for this anti-
in£ammatory e¡ect. 22ROH also caused a partial
reduction in ear thickness in LXRa / animals, how-
ever (E50% of that observed in wild-type mice), sug-
gesting that this receptor also mediates the anti-
in£ammatory e¡ects of oxysterols. Both ear thickness
and weight increased (E1.5-fold) in the oxazolone-in-
duced allergic dermatitis model, and 22ROH and
GW3965 reduced in£ammation by E50% and E30%,
respectively. Finally, immunohistochemistry demon-
strated an inhibition in the production of the pro-
in£ammatory cytokines interleukin-1a and tumor
necrosis factor a in the oxysterol-treated sites from both
TPA- and oxazolone-treated animals. These studies de-
monstrate that activators of LXR display potent anti-
in£ammatory activity in both irritant and allergic con-
tact models of dermatitis, requiring the participation of
both LXRa and LXRb. LXR activators could provide a
new class of therapeutic agents for the treatment of cuta-
neous in£ammatory disorders. Key words: in£ammation/
keratinocyte/nuclear hormone receptors/oxysterols. J Invest
Dermatol 120:246 ^255, 2003
N
uclear hormone receptors, the largest known fa-
mily of transcription factors, have been divided
into four major subgroups based upon their
dimerization and DNA binding properties
(Mangelsdorf and Evans, 1995). The class II sub-
family includes the retinoic-acid-activated receptor (RAR), thyr-
oid hormone receptor, vitamin D receptor, peroxisome-
proliferator-activated receptors (PPARs), and liver X receptor
(LXR). These receptors recognize small hydrophobic com-
pounds, such as 1,25(OH)2-vitamin D, free fatty acids, retinoids,
thyroid hormone, and certain oxysterols. Activation of class II re-
ceptors requires heterodimerization with RXR, which allows for
optimal regulation of gene expression. In the epidermis, ligand
activation of several class II nuclear hormone receptors, including
RAR, PPARa, vitamin D receptor, and LXR, regulates kerati-
nocyte proliferation and di¡erentiation in vitro and in vivo (Bikle,
1996; Eichner et al, 1996; Fisher and Voorhees, 1996; Kang et al,
1996; Hanley et al, 1997, 1998; Komuves et al, 2000). In addition,
ligands of RAR, vitamin D receptor, and PPAR display selected
types of anti-in£ammatory activity (Devchand et al, 1996; Muller
and Bendtzen, 1996; Duvic et al, 1997; Deluca and Cantorna, 2001).
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Recent studies by our laboratory have shown that activators of
PPARa inhibit both irritant and allergic contact dermatitis in
murine skin (Sheu et al, 2002).
LXRs were classi¢ed initially as orphan members of the nucle-
ar receptor superfamily, due to the unknown nature of their li-
gands. LXRa and LXRb are now recognized to bind certain
endogenous oxysterols, including 22(R)-hydroxycholesterol
(22ROH), 24(S)-hydroxycholesterol, and 24(S),25-epoxycholes-
terol (Janowski et al, 1996; Lehmann et al, 1997; Peet et al, 1998).
Activation of LXR in extracutaneous tissues regulates important
steps in cholesterol, fatty acid, and bile acid metabolism (Peet
et al, 1998; Chawla et al, 2001). Two genes, a and b, encode the
LXR paralogs. Whereas LXRa is expressed predominately in
the liver and to a lesser extent in the kidney, spleen, adrenal
gland, and the small intestine (Willy et al, 1995), LXRb is ubiqui-
tously expressed (Song et al, 1995). Our laboratory has shown that
both LXRa and LXRb are present in cultured human keratino-
cytes and in fetal rat epidermis (Hanley et al, 1999; 2000). LXRb
is the predominate isoform in adult mouse epidermis, however
(Komuves et al, 2002). Recently, we demonstrated that topical ap-
plication of oxysterols to murine epidermis stimulates keratino-
cyte di¡erentiation and inhibits proliferation (Komuves et al,
2002). Moreover, these e¡ects still occurred in LXRa / mice,
but not in LXRb / animals, indicating that the stimulation
of keratinocyte di¡erentiation and the inhibition of proliferation
induced by oxysterols is mediated predominately by LXRb
(Komuves et al, 2002). In addition, oxysterols accelerate the
formation of the epidermal permeability barrier during fetal de-
velopment (Hanley et al, 1999; 2000), and topical oxysterols
improve barrier homeostasis following barrier disruption in
normal mice (Komuves et al, 2002). Furthermore, in an animal
model of epidermal hyperplasia (Komuves et al, 2002), oxysterol
treatment largely normalized structure, barrier function, and
di¡erentiation, suggesting that LXR activators could provide a
new category of therapeutic agents for cutaneous diseases
that are associated with hyperproliferation and/or disordered
di¡erentiation.
Activation of several members of the class II family of nuclear
hormone receptors can regulate in£ammation. Oxysterols, which
activate LXR, inhibit the secretion of proin£ammatory cyto-
kines, such as tumor necrosis factor (TNF) and interleukin
1 (IL-1), by macrophages and inhibit lymphocyte activation
(Ohlsson et al, 1996). Although these observations suggest that
oxysterols could be anti-in£ammatory, other studies have shown
that oxysterols stimulate the secretion of IL-8 by macrophages, a
proin£ammatory event (Liu et al, 1997). Moreover, whether the
e¡ects of oxysterols on macrophages and lymphocytes are
mediated by LXR or whether they occur via other pathways is
unknown. The primary purpose of this study was to determine
whether topical applications of oxysterols and/or GW3965, a non-
sterol activator of LXR, attenuate in£ammation in two distinct
models of cutaneous in£ammation, irritant and allergic contact
dermatitis. Moreover, we addressed whether LXRa and/or LXRb
mediate this anti-in£ammatory e¡ect.The results of this study in-
dicate that agonists of LXR, when applied topically to the skin,
display receptor-mediated, via both LXRa and LXRb, anti-in-
£ammatory behavior.
MATERIALS AND METHODS
Animal models and tissue preparation Adult CD1 male and female
mice, 6^10 wk of age, were purchased from Charles River Laboratories
(Wilmington, MA) for use in this study. Phorbol 12-myristate-13-acetate
(TPA) induced irritant contact dermatitis was instituted by the topical
application of 10 ml 0.03% (wt/vol in acetone) TPA to both the inner and
outer surface (20 ml total) of the left ears. Acetone alone (vehicle)
was applied to the right ears. Forty-¢ve minutes and 4 h after
TPA application, 20 ml of test compounds, 22ROH (10 mM), 25-
hydroxycholesterol (25OH; 10 mM), and GW3965 (10 mM), known LXR
agonists, were applied to both surfaces of both the left and right ears (40 ml
total per ear). Identical treatments were performed with 20 ml of 0.05%
clobetasol (1.1 mM), a topical anti-in£ammatory glucocorticoid, which
served as a positive control. Cholesterol (1%, 2.5 mM), which neither
binds nor activates LXR, was applied in a similar fashion as a negative
control. Control animals were treated similarly with acetone alone,
serving as a vehicle control. All chemical compounds were purchased
from Sigma (St. Louis, MO) and were dissolved in absolute acetone
(reagent grade) vehicle. GW3965 was synthesized by GlaxoSmithKline
High Throughput Chemistry, as described previously (Collins et al,
submitted).
Allergic contact dermatitis was induced by sensitization (for 2 d) on the
shaved backs of CD1 female mice with 20 ml of 15% (wt/vol in acetone)
oxazolone (4-ethoxymethylene-2-phenyl-2-oxazolin-5-one) once a day,
followed by challenge on day 7 with a single topical application of 10 ml
oxazolone (2%) to the inner and outer surface of the left ears. Acetone
alone (10 ml) was applied to the right ears. This challenge was followed by
treatment with 22ROH (10 mM), GW3965 (10 mM), clobetasol (0.05%), or
acetone at 45 min and 4 h, as described previously.
Eighteen hours after the in£ammatory insult induced by either TPA or
oxazolone, in£ammation was assessed as the percentage increase in ear
thickness and/or ear weight in the treated left ear versus the vehicle-treated
right ear. Ear thickness was measured with a digital caliper (Mitutoyo,
Tokyo, Japan), followed by a 6 mm punch biopsy to ascertain changes in
ear weights. The extent of in£ammation was quantitated according to
the following equation: ear swelling (%)=100 (ab)/b, where a is the
thickness/weight of the left (treated) ear and b is the thickness/weight of
the right (untreated control) ear.
After samples were obtained for assessment of ear thickness/weight,
biopsies were obtained from adjacent sites for routine histopathology
(¢xation in 4% freshly prepared paraformaldehyde in phosphate-bu¡ered
saline), or for immunohistochemical analysis (directly frozen in liquid
nitrogen).
LXR-de¢cient animals Age- and sex-matched controls from the same
genetic background and LXRa /, LXRb /, and LXRa/b /
mice, produced as described previously (Peet et al, 1998), were used in this
study. The irritant contact dermatitis model (TPA) was performed in an
identical fashion in these mice, as described above for CD1 mice. Each
group of animals was divided randomly, half receiving 22ROH and the
other half receiving vehicle alone, at 45 min and 4 h post TPA-induced
in£ammation. Ear thickness was measured at 18 h as described above, but
weight determinations were not performed due to the small numbers of
knockout animals available. Biopsies then were taken for hematoxylin and
eosin staining and immunohistochemistry.
Epidermal function measurements Basal cutaneous permeability
barrier function was determined by measuring transepidermal water loss
(TEWL) with an electronic water analyzer (MEECO, Warrington, PA).
The kinetics of barrier recovery were then determined after acute
disruption by sequential applications of cellophane tape (Scotch tape, 3M)
(TEWLX 6^8 mg per cm2 per h), at 3 and 6 h postdisruption, as described
previously (Komuves et al, 2000). Stratum corneum integrity was de¢ned
as the number of tape strips required to produce a predetermined elevation
in TEWL (Fluhr et al, 2001). Stratum corneum cohesion was de¢ned as the
amount of protein removed per stripping, measured with a BioRADAssay
Kit (Hercules, CA), using bovine plasma gamma globulin as the standard,
as described previously (Fluhr et al, 2001). Changes in surface pH were
measured with a £at glass electrode (Mettler-Toledo, Giessen, Germany),
using a pH meter (Skin pH Meter PH 900, Courage and Khazaka,
Cologne, Germany).
Immunohistochemistry Both para⁄n sections (6 mm) and cryosections
(5 mm) were used to detect TNF-a and IL-1a in this study. Cryosections
alone were assessed in the LXR-de¢cient animals. Para⁄n-embedded,
paraformaldehyde-¢xed sections were processed as described previously
(Sheu et al, 2002), using polyclonal rabbit antimouse primary antibodies
speci¢c for IL-1a (R&D Systems, Minneapolis, MN) and polyclonal goat
antimouse speci¢c for TNF-a (Santa Cruz Biotechnology, Santa Cruz,
CA). Peroxidase activity was revealed with 3,30 -diaminobenzidine
substrate (Vector Laboratories, Burlingame, CA), and methyl green was
used as a counterstain. The same antibodies were used for
immunohistochemical localization of IL-1a and TNF-a in cryosections.
After washing in TrisHCl bu¡er, the sections were incubated with
blocking bu¡er for 30 min at room temperature, followed by incubation
with primary antibody (1: 500) in blocking bu¡er for 2 h. Before
incubation with the secondary antibody (1: 200) for 45 min, the sections
were washed in TrisHCl bu¡er and incubated for 10 min with
levamisole (0.05%) to inhibit endogenous alkaline phosphatase activity.
Localization was achieved by the avidinbiotin peroxidase technique,
using alkaline phosphatase as the chromagen (reaction time, 13 min and
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45 min for IL-1a and TNF-a, respectively). The sections were rinsed with
ddH2O, dehydrated, and mounted (Cytoseal 60, Stephens Scienti¢c,
Kalamazoo, MI). Nonspeci¢c binding of secondary IgG was not seen
when the primary antibody was omitted.
Microscopy and imaging The sections were examined with a Zeiss
(Axioplan 2) microscope (Jena, Germany) using bright-¢eld optics.
Digital images were captured with AxioVision software 2.05 (Carl Zeiss
Vision, Munich, Germany). Photos were prepared using Adobe Illustrator
(Adobe Systems, MountainView, CA).
Statistical analyses All statistical analyses were performed using Prism
3 software (Graph Pad Software, San Diego, CA). Results were compared
between multiple groups, using ANOVA, and expressed as mean7 SEM.
When results between pairs were analyzed, the Student’s t test was used.
RESULTS
Activators of LXR inhibit TPA-induced contact
dermatitis We initially examined the anti-in£ammatory e¡ect
of LXR activators in a TPA-induced, irritant contact dermatitis
murine model. Both ear thickness (Fig 1A) and ear weight
(Fig 1B) markedly increased (1.85-fold and 1.91-fold,
respectively) after treatment with TPA. Application of vehicle
(acetone) alone did not signi¢cantly a¡ect TPA-induced
in£ammation (1.60-fold and 1.78-fold, for ear thickness and
weight, respectively). In contrast, treatment with either 22ROH
or 25OH markedly attenuated the TPA-induced increase in ear
thickness and ear weight. Because the LXR activators were
applied topically, high concentrations (10 mM) were used in
order to ensure activation of the target cells. Treatment with
22ROH decreased both ear thickness and ear weight by 51%
and 56%, respectively, versus the vehicle control, whereas 25OH
decreased thickness and weight by 57% and 69%, respectively
(Fig 1A, B). These anti-in£ammatory e¡ects were comparable to
those achieved by topical clobetasol, a potent glucocorticoid (ear
thickness and weight were decreased by 68% and 61%,
respectively). Treatment with cholesterol, however, which does
not activate LXR, did not alter the extent of TPA-induced
in£ammation insult (Fig 1A, B). Finally, because oxysterols have
biologic e¡ects other than activating LXR, we next employed a
nonsterol activator of LXR, GW3965. As shown in Fig 1,
GW3965 reduced ear thickness and ear weight by 40% and
38%, respectively, following TPA treatment. These results
strongly suggest that LXR activation and not other, nonspeci¢c
e¡ects of oxysterols account for the inhibition of TPA-induced
in£ammation.
Hematoxylin and eosin stained sections from the same TPA-
treated mice are shown in Fig 2. TPA application alone (Fig 2B)
produced a marked increase in ear thickness and an abundance of
in£ammatory cells in¢ltrating the epidermis and dermis (Fig 2A
vs 2B). In contrast, 22ROH treatment markedly reduced both ear
thickness and the extent of the in£ammatory in¢ltrate in the
epidermis and dermis (Fig 2B vs 2C). Again, the reduction in
in£ammation was similar to that seen with clobetasol treatment
(Fig 2C vs 2D). These results further demonstrate the anti-
in£ammatory properties of oxysterols in the TPA-irritant contact
dermatitis model.
Stratum corneum function remains normal in LXRa,
LXRb, and LXRa/b knockout mice Previous studies with
LXRb ^/^ and LXRa/b ^/^ mice demonstrated a slight
decrease in the expression of epidermal di¡erentiation markers,
with thinning of the normal epidermis, whereas such changes
did not occur in LXRa ^/^ mice (Komuves et al, 2002). We
therefore next determined whether the modest morphologic
alterations that occur in animals de¢cient in LXRb result in
functional abnormalities. In all three strains of LXR-de¢cient
mice (LXRa, LXRb, and LXRa/b ^/^), basal TEWL and the
kinetics of barrier recovery following acute barrier disruption
were similar to rates observed in wild-type littermates (data not
shown). In addition, stratum corneum cohesion and integrity
were similar in LXR-de¢cient mice and control mice (data not
shown). Lastly, surface pH was not altered by the absence of
either LXRa or LXRb (data not shown). Thus, LXR de¢ciency
does not produce signi¢cant functional cutaneous abnormalities.
The anti-in£ammatory e¡ects of oxysterols are mediated by
LXR In order to determine de¢nitively whether the anti-
in£ammatory e¡ects of oxysterols are mediated by LXR, we
next compared the anti-in£ammatory e¡ects of oxysterols on
TPA-induced in£ammation in LXRa ^/^, LXRb ^/^, and
LXRa/b ^/^ versus wild-type mice. Treatment with TPA
increased ear thickness to a similar extent in LXRa- and LXRb-
de¢cient mice compared to wild-type mice. Yet,TPA-induced ear
thickness was blunted in the LXRa/b ^/^ double knockout mice
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Figure1. Activators of LXR reduce TPA-induced in£ammation.
Mice were treated with 10 ml of TPA (0.03%) to the inner and outer sur-
faces of the left ears. The mice were treated topically on both ears 45 min
and 4 h after TPA application with either clobetasol (0.05%), the LXR li-
gands 22ROH (10 mM) and 25OH (10 mM), cholesterol (1.0%), or
GW3965 (10 mM) (a nonsterol activator of LXR). A separate vehicle con-
trol is shown for the GW3965 experiment because the experiment was car-
ried out at a di¡erent time. At 18 h post TPA application, ear thickness and
ear weight (6 mm punch) were measured. Treatment with LXR activators
or clobetasol results in a marked reduction in ear thickness (A) and ear
weight (B) compared to treatment with vehicle alone. Cholesterol, which
does not activate LXR, has no signi¢cant e¡ect. Results are shown as the
mean percentage increase in ear thickness and weight (mean 7 SEM;
n¼ 4^8; npo0.01, nnpo0.001). Statistical signi¢cance was determined
using ANOVA for multiple groups and a Student’s t test for two groups.
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(not shown). Treatment with 22ROH following TPA resulted in
a similar reduction in ear thickness in the LXRwild-type control
mice as seen in the CD1 mice (Fig 1 vs Fig 3). In contrast,
22ROH treatment did not signi¢cantly reduce ear thickness in
the LXRb ^/^ or LXRa/b ^/^ animals (Fig 3). Clobetasol
treatment resulted in a reduction in ear thickness in LXRb ^/^
mice, however, to a degree virtually identical to that seen in
wild-type mice (LXRb ^/^ 29% decrease versus wild-type 34%,
not signi¢cant, n¼ 3^4). These results indicate that the failure of
22ROH to inhibit TPA-induced in£ammation in LXRb ^/^
animals is not due to a general impairment of these animals to
elicit an anti-in£ammatory reaction. Finally, whereas treatment
with 22ROH partially reduced the ear thickness in the LXRa
^/^ animals, the extent of anti-in£ammatory e¡ects was less than
those observed in the wild-type animals (32% vs 58%,
respectively). These ¢ndings indicate that the anti-in£ammatory
e¡ects produced by oxysterol treatment are inhibited by LXR,
and primarily require LXRb, but that LXRa is also of
importance.
Oxysterols reduce oxazolone-induced allergic contact
dermatitis We next examined the e¡ects of the LXR agonist
22ROH in a model of allergic contact dermatitis. Fig 4(A), (B)
demonstrates the marked increase in both ear thickness and
weight induced by topical oxazolone applications to sensitized
animals (E1.5-fold). Treatment with 22ROH reduced the
oxazolone-induced in£ammation, as shown by both decreased
ear thickness (Fig 4A) and decreased ear weight (Fig 4B) (58%
and 55%, respectively). Moreover, treatment with a nonsterol
activator of LXR, GW3965, also signi¢cantly decreased ear
thickness and ear weight, by 28% and 26%, respectively.
Clobetasol (0.05%) treatment produced a stronger anti-
in£ammatory e¡ect than that observed with the LXR activators
at the concentrations employed here (over a 90% reduction in ear
Figure 2. In£ammation induced byTPA is reduced by topical application of LXR activators.Ten microliters of TPA (0.03%) was applied to the
left ears (both surfaces) of mice. Forty-¢ve minutes and 4 h after TPA application, the animals were treated topically with activators of LXR, clobetasol, or
vehicle (acetone). The animals were sacri¢ced at 18 h after TPA application and biopsies of the ears were obtained. The specimens were ¢xed in 4% paraf-
ormaldehyde and stained with hematoxylin and eosin. A marked increase in ear swelling and in£ammatory cells was found in the vehicle-treated ear (B).
Treatment with 22ROH (C) reduces ear thickness and the degree of in£ammatory in¢ltrate, similar to clobetasol treatment (D). A normal untreated mouse
ear is provided for comparison (A). Sections above are representative ¢ndings from three animals per group. Scale bar: 50 mm.
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thickness and weight). Finally, hematoxylin and eosin stained
sections demonstrated a marked increase in ear thickness
with an abundance of in£ammatory cells in both epidermis
and dermis in oxazolone-treated animals, changes that were
markedly reduced by 22ROH treatment (Fig 5). Thus,
oxysterols reduce in£ammation in a murine model of allergic
contact dermatitis.
LXR activators inhibit TNF-a and IL-1a generation in wild-
type but not in LXRb-de¢cient mice Keratinocytes generate
the primary cytokines TNF-a and IL-1a in response to a variety
of forms of cutaneous injury, leading to a downstream
in£ammatory response (Piguet, 1993; Murphy et al, 2000).
Previous studies by our laboratory have shown that both
epidermal TNF-a and IL-1a immunoreactivity increase
following either TPA- or oxazolone-induced in£ammation
(Sheu et al, 2002). Using a similar immunohistochemical
approach, we next examined whether 22ROH treatment
decreased the production of TNF-a and IL-1a in response to
TPA or oxazolone challenge. Figs 6 and 7 demonstrate a
comparable decrease in TNF-a and IL-1a immunostaining in
both the epidermis and dermis of 22ROH- and clobetasol-
treated animals in both the irritant and allergic contact
dermatitis models. These ¢ndings provide further evidence
that treatment with oxysterols inhibits these in£ammatory
responses.
To further elucidate the importance of LXRb in the anti-
in£ammatory e¡ects produced by oxysterols, we next examined
whether treatment with 22ROH would decrease the production
of TNF-a and IL-1a in animals lacking LXRb, using
immunohistochemical techniques. Fig 8(A), (B) demonstrates a
decrease in the staining of TNF-a and IL-1a, respectively, in the
epidermis and dermis of wild-type animals after treatment with
22ROH in the irritant contact dermatitis model. A decrease in
immunostaining was not evident after 22ROH treatment in
TPA-challenged LXRb ^/^ animals, however. These ¢ndings
provide further evidence that oxysterol activators reduce
in£ammation by an LXRb-speci¢c mechanism.
DISCUSSION
This study is the ¢rst de¢nitive demonstration that activators of
LXR possess anti-in£ammatory properties. In both TPA-induced
in£ammation, a model of irritant contact dermatitis, and oxazo-
lone-induced allergic contact dermatitis, both oxysterol activation
of LXR and GW3965, a nonsterol activator of LXR, reduce
Figure 3. 22ROH does not reduce TPA-induced ear in£ammation
in LXRb ^/^ and LXRa/b ^/^ mice and 22ROH partially reduces
in£ammation in LXRa ^/^ mice. Ear swelling with TPAwas induced
in the LXR-de¢cient animals as described for the CD1 animals. Each set of
knockout animals was treated with vehicle or 22ROH and ear thickness
was measured 18 h after TPA application. Ear thickness is markedly reduced
after topical treatment with 22ROH (10 mM) in wild-type animals.
22ROH does not reduce the swelling in LXRb ^/^ or LXRa/b ^/^ ani-
mals. 22ROH has a partial e¡ect in the LXRa ^/^ mice, as ear swelling is
somewhat diminished. Results are shown as the reduction (percentage) in
ear thickness observed following treatment with 22ROH versus vehicle
control. Data represent means7 SEM; n¼ 4^8, po 0.01. Statistical analy-
sis was performed using Student’s t test.
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Figure 4. Activators of LXR reduce in£ammation in an allergic
contact dermatitis model. Animals were sensitized on shaved backs with
2% oxazolone (day 0), followed by application of 15% oxazolone (day 7) to
the left ear. The mice were treated topically on both ears 45 min and 4 h
after oxazolone application with either 22ROH (10 mM), clobetasol
(0.05%), GW3965 (a nonsterol LXR activator) (10 mM), or vehicle (acet-
one). At 18 h post oxazolone application, ear thickness and ear weight (6
mm punch) were measured. Ear thickness (A) and ear weight (B) are mark-
edly increased in oxazolone-induced allergic contact dermatitis. 22ROH
(10 mM) and GW3965 (10 mM) treatment reduces oxazolone-induced ear
thickness (A) and weight (B). Clobetasol (0.05%) treatment nearly elimi-
nates the swelling. Results are shown as the mean percentage increase in
ear thickness and weight (mean 7 SEM; n¼ 5^7, npo 0.05, nnpo 0.01,
nnnpo 0.001). Statistical signi¢cance was determined using ANOVA and
Student’s t test.
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cutaneous in£ammation. Thus, two di¡erent types of LXR
activators are able to decrease in£ammation in two di¡erent, in
vivo models of cutaneous in£ammation. Oxysterols were some-
times more e¡ective in inhibiting in£ammation than the nonster-
ol LXR activator GW3965 in the topical in£ammation assays. A
likely reason for this di¡erence in potency is that the ability of
oxysterols to permeate an intact stratum corneum and activate
keratinocytes is greater than for the nonsterol LXR activator
GW3965. In contrast, cholesterol, a sterol that does not activate
LXR, exhibited no anti-in£ammatory activity in these models.
Moreover, we showed that in the TPA-irritant contact dermatitis
model, the anti-in£ammatory properties of the LXR activators
are of a magnitude similar to that seen with clobetasol, a potent
topical glucocorticoid. In the oxazolone allergic contact dermati-
tis model, however, the anti-in£ammatory properties of gluco-
corticoids exceed those seen with the LXR activators at the
doses employed here. As allergic contact dermatitis requires an
adaptive immune response involving T lymphocytes, glucocorti-
coids could inhibit these pathways in the immune system more
e¡ectively than can LXR agonists, which could account for the
greater anti-in£ammatory activity in the allergic contact dermati-
tis model (Leung et al, 1999; Weston and Bruckner, 2000). Yet,
because glucocorticoids can exhibit adverse side-e¡ects, their
usefulness as anti-in£ammatory agents is limited (Ashwell et al,
2000). In fact, whereas exogenous glucocorticoids impair cuta-
neous permeability barrier homeostasis, as well as stratum cor-
neum integrity/cohesion,2 we have shown that LXR activators
instead improve stratum corneum barrier function (Komuves
et al, 2002). Thus, LXR activators could display more discrete
Figure 5. LXR activators decrease oxazolone-induced in£ammation. Allergic contact dermatitis was induced by primary sensitization on day 0
with 2% oxazolone (20 ml) to the shaved backs of mice, followed by application of 15% oxazolone (10 ml) to the left ear on day 7. Forty-¢ve minutes and
4 h after TPA application, the animals were treated topically with either clobetasol (0.05%), 22ROH (an oxysterol), or vehicle (acetone). The animals were
sacri¢ced at 18 h after TPA application and biopsies of the ears were obtained. The specimens were ¢xed in 4% paraformaldehyde and stained with hema-
toxylin and eosin. Topical oxazolone application results in an increase in ear thickness and the amount of in£ammatory cells (B). Treatment with 22ROH
(D) and clobetasol (C) reduces ear thickness and the number of in£ammatory cells. A normal untreated mouse ear (A) is provided for comparison. Sections
above are representative ¢ndings from three animals per group. Scale bar: 50 mm.
2Kao JS, Fluhr JW, Man M et al (Abstr.)
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and less global e¡ects than glucocorticoids, suggesting that they
can be useful for the treatment of in£ammatory skin disorders.
Whereas these and previous in vitro studies suggest that
oxysterols possess anti-in£ammatory properties (Ohlsson et al,
1996), oxysterols display biologic e¡ects beyond the activation of
LXR. For example, oxysterols inhibit the proteolytic conversion
of SREBP to an active transcription factor, which accounts
for the ability of oxysterols to inhibit cholesterol synthesis and
to reduce LDL receptor levels (Brown and Goldstein, 1997).
Yet, in this study we demonstrate that a nonsterol activator of
LXR, GW3965, also displays anti-in£ammatory properties,
further increasing the likelihood that the cutaneous anti-
in£ammatory e¡ects of oxysterols are mediated via LXR.
Alternatively, the oxysterol compounds may regulate non-LXR
pathways, such as the inhibition of SREBP signaling. To
demonstrate de¢nitively the importance of LXR, we carried
Figure 6. Oxysterols reduce expression of IL-1a and TNF-a in TPA-induced model of irritant contact dermatitis. Ear samples were obtained 18
h after TPA-induced contact dermatitis. The mice were treated 45 min and 4 h after TPA application as indicated. Paraformaldehyde-¢xed sections were
stained with rabbit polyclonal anti-IL-1a and polyclonal goat anti-TNF-a antibodies. IL-1a and TNF-a immunoreactivity was visualized by biotinylated
secondary antibodies in combination with the 3,3-diaminobenzidine technique (brown color) and counterstained with methyl green. Immunohistochem-
ical staining demonstrates a more pronounced expression of proin£ammatory cytokines IL-1a andTNF-a in the epidermis and dermis following treatment
withTPA and vehicle alone. After treatment with 22ROH (10 mM) or clobetasol (0.05%) followingTPA application, IL-1a andTNF-a staining is reduced.
Insert shows higher magni¢cation. Sections above are representative ¢ndings from three animals per group. Scale bar: 10 mm.
Figure 7. Oxysterols reduce expression of IL-1a and TNF-a in oxazolone-induced model of allergic contact dermatitis. Ear samples were
obtained 18 h after oxazolone-induced allergic contact dermatitis to sensitized mice. The mice were treated 45 min and 4 h after oxazolone application as
indicated. Paraformaldehyde-¢xed sections were stained with rabbit polyclonal anti-IL-1a and polyclonal goat anti-TNF-a antibodies. IL-1a and TNF-a
immunoreactivity was visualized by biotinylated secondary antibodies in combination with the 3,3-diaminobenzidine technique (brown color) and coun-
terstained with methyl green. Immunohistochemical staining demonstrates an increase in IL-1a and TNF-a in the epidermis and dermis of oxazolone-
treated animals after treatment with vehicle (acetone) alone. After treatment with 22ROH (10 mM) or clobetasol (0.05%), IL-1a and TNF-a staining is
reduced. Note the negative control (counterstained with nuclear fast red) provided for comparison. Insert shows higher magni¢cation. Sections above are
representative ¢ndings from three animals per group. Scale bar: 10 mm.
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out studies using LXR-de¢cient animals. Oxysterols did
not inhibit in£ammation in either LXRb ^/^ or LXRa/b ^/^
mice, indicating that the anti-in£ammatory properties of
oxysterols on cutaneous in£ammation require LXRb, and
that LXRa alone cannot compensate for an absence of
LXRb.
Figure 8. Oxysterols do not reduce IL-1a and TNF-a expression in LXRb ^/^ animals following TPA-induced in£ammation.Wild-type and
LXRb-de¢cient mice were treated withTPA followed by 22ROH and vehicle (acetone) as described for the wild-type animals. Ear biopsies were taken 18 h
after TPA application and cryosections were obtained. The samples were stained with rabbit and goat polyclonal antibodies to TNF-a (A) and IL-1a (B),
respectively. Bound antibodies were detected with secondary biotin-conjugated antibodies in combination with alkaline phosphatase (purple color). No
counterstaining was performed. The reduction in IL-1a and TNF-a expression induced following treatment with 22ROH compared to vehicle treatment
in the wild-type animals is not observed in the LXRb ^/^ animals.Treatment with 22ROH does not reduce IL-1a andTNF-a staining compared to vehicle
in the LXRb ^/^ mice. Scale bar: 10 mm.
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In the LXRa-de¢cient mice the situation is more complex, as
oxysterols are able to decrease in£ammation but the anti-in£am-
matory e¡ects are reduced in comparison to wild-type mice
(E50% reduction versus wild-type mice). In previous studies
using northern blotting we did not detect LXRa in mouse epi-
dermis (Komuves et al, 2002). In both cultured human keratino-
cytes and fetal rat epidermis, however, LXRa is easily observed
(Hanley et al, 1999; 2000). It is possible that LXRa is present in
small quantities in mouse epidermis, and that it plays a separate
role in the anti-in£ammatory properties of oxysterols, which can-
not be compensated for by the presence of LXRb. Alternatively,
LXRa could be present in in£ammatory cells, dermal cells, or
other cells that contribute to the cutaneous in£ammatory re-
sponse and oxysterols may reduce in£ammation by activating
LXRa in these cells.
The secretion of TNF-a and IL-1a by keratinocytes in re-
sponse to injury mediates the cutaneous in£ammatory response
(Piguet, 1993; Murphy et al, 2000). In this study, we demonstrate
that activators of LXR inhibit the secretion of TNF-a and IL-1a
in both the irritant and allergic models of contact dermatitis.
Oxysterols did not reduce cytokine generation in LXRb-de¢-
cient mice. Together, these results indicate that LXR activation
inhibits cytokine secretion, at least in part, accounting for the
anti-in£ammatory properties observed in these studies.
Ligands of other class II nuclear hormone receptors, such as
PPAR and the vitamin D receptor, have been shown to have
anti-in£ammatory properties (Devchand et al, 1996; Muller and
Bendtzen, 1996; Duvic et al, 1997; Staels et al, 1998; Delerive et al,
1999; 2000; Deluca and Cantorna, 2001). The expression of many
genes required for the in£ammatory response are regulated by
nuclear factor kB (NF-kB) activation (Ghosh et al, 1998), and both
the PPARs and the vitamin D receptor have been shown to
inhibit NF-kB, thereby reducing in£ammation (Yu et al, 1995;
Delerive et al, 2001). In vascular smooth muscle cells, oxysterols
inhibit lipopolysaccharide-induced activation of NF-kB (Ares et
al, 1995).Whether the e¡ects of LXR activation on cutaneous in-
£ammation are mediated by alterations in NF-kB and/or other
pathways, however, remains to be determined.
Previous studies have demonstrated that LXR activators stimu-
late epidermal di¡erentiation, improve permeability barrier
homeostasis, and inhibit epidermal proliferation (Komuves et al,
1998; 2002; Hanley et al, 2000). In this study we demonstrate that
LXR activators also possess anti-in£ammatory properties. A
number of cutaneous disease states, such as psoriasis, are charac-
terized by hyperproliferation, in£ammation, decreased di¡e-
rentiation, and impaired permeability barrier homeostasis (Chris-
tophers and Mrowietz, 1999). Given the pro¢le of activity of
LXR activators, it is possible that compounds that activate LXR
will be useful in the treatment of psoriasis and other in£amma-
tory dermatoses. Additionally, if further studies demonstrate that
LXR activators also reduce in£ammation in extracutaneous tis-
sues, these compounds could be useful in the treatment of a wide
variety of other in£ammatory disorders.
In summary, this study demonstrates conclusively that com-
pounds that activate LXR reduce in£ammation in animal models
of irritant and allergic contact dermatitis by a receptor-mediated
process that involves suppression of cytokine production.
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